Pharmacology of nerve growth factor output by target cells.
Tuttle
J B
JB
Department of Neuroscience, University of Virginia Health Sciences Center, Charlottesville 22908.
Creedon
D J
DJ
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001011:Aorta; D001127:Arginine Vasopressin / Q000494:pharmacology; D000077214:Becaplermin; D002478:Cells, Cultured; D005576:Colforsin / Q000494:pharmacology; D016895:Culture Media, Serum-Free; D003609:Dactinomycin / Q000494:pharmacology; D004357:Drug Synergism; D007700:Kinetics; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism*; D009414:Nerve Growth Factors / Q000096:biosynthesis* / Q000378:metabolism; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D016895:Culture Media, Serum-Free; D009414:Nerve Growth Factors; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D000804:Angiotensin II; D001127:Arginine Vasopressin; D000077214:Becaplermin; D003609:Dactinomycin; D005576:Colforsin